All cancer treatments are destructive-the cutting and mutilation of surgery, the burning of radiation, and the poisoning of chemotherapy-but cancer is a remorseless disease and "Diseases desperate grown by desperate appliance are relieved, or not at all."' Modern cancer chemotherapy is the product of chemical warfare and animal studies. Many of the victims of "mustard gas" poisoning in the first world war were found-unexpectedly-to have aplasia of the bone marrow at necropsy.2 Years later research on mice developed this chance finding into a treatment for malignant lymphomas and leukaemias using drugs related to mustard gas.3 The drugs used in such treatments were cell poisons, and they were aptly named cytotoxic. Today there are 30 or more different anticancer drugs available, some more specific than others, and their use is now described as cancer chemotherapy; nevertheless, the agents used are still cell poisons.
Inevitably cancer chemotherapy will cause emotional distress. Patients are mostly aware that if such treatment is recommended their condition is serious if not desperate, and many will become severely depressed. They are not deceived by the blandness of the word chemotherapy. They know that the drugs used are potent and dangerous and the bush telegraph alerts them to many of the possible side effects and complications. They will know of patients who have had drug treatment for many months, with all its miseries, and who have died without receiving any benefit. Less well known to the public are the successes of chemotherapy-the cures of leukaemias, lymphomas, Hodgkin's disease, testicular and some ovarian cancers, and cancers in children; long remissions in other malignancies; and increased periods free of active disease and consequent improvement in quality of life.
Among the factors that may contribute to patients' emotional distress the most important seems to be coming to terms with the reality that their disease is severe and possibly fatal. Lack of information on the aims of the treatment and the possible outcomes adds to patients' concerns and fears. A further important factor is the physical effccts of the treatment: nausea, vomiting, diarrhoea, general debility, and alopecia; loss of taste, appetite, and sexual function all contribute to feelings of helplessness and lack of control. The relentless progression of courses of treatment can undermine the most determined. Knowing in advance that once again a period of sickness and ill health must be endured may produce "conditioned vomiting," needle phobia, and even refusal of treatment. Often there are no indicators or markers to monitor the response to treatment,4 making perseverance a matter of If a malignant tumour can be cured by chemotherapy, the patient (and often the relatives) should be fully informed of the aims of the treatment, the chances of success, and the details of the proposed course. Any fears and anxieties should be discussed, and frequent reviews are needed during and after the treatment to reassess, reassure, and encourage. Different patients will want to know and understand different amounts, and it may often be necessary to give repeated explanations to be sure that the patient has as much information as he or she wants.
If treatment is to be given with the hope of procuring a long remission or relief of distressing symptoms a similar approach should be adopted and the chances of benefit honestly evaluated and discussed. Some well informed patients may decide against chemotherapy, considering that the demands of the treatment outweigh any possible relief which may or may not be achieved. Others will be glad to accept any offer of treatment, and will be prepared to cope with all the disadvantages in the hope of a successful outcome, and they will have a goal to work towards, however small. Plainly the patient will have to come to terms with the illness, and this may need the well timed help of a counsellor, who may be a doctor, nurse, social worker, or psychiatrist, or even a close friend or relative. Regular support during the treatment will help to minimise the distress caused by the side effects of the drugs. Antiemetics can usually control sickness, supplying an attractive wig in advance of alopecia helps, and use of a "cold cap" may even prevent loss of hair. Sensible use of hypnotics can ensure a good night's sleep. Explanation that the problems are expected and that things are not going wrong may often relieve anxiety without the need for tranquillisers, but sometimes help is needed with severe depression.
Patients seem to cope with chemotherapy in the same way that they respond to other life events. Some take it in their stride, others manage with difficulty, and some not at all. Charting reactions and miseries seems an insensitive procedure and unlikely to improve the patient's lot, but indices of performance status are of value as they are a constant reminder that a whole person is being treated and not just a disease or a blood count.6 The Karnofsky index, although 20 years old, has stood the test of time and is often more useful than more elaborate scores.
The emotional distress caused by cancer chemotherapy must not be underestimated, but it is not difficult to understand. What is difficult is finding teams of experienced staff who can organise and supervise the treatments so that they can be completed without too much anxiety and distress and without patients "dropping out." Such teams need also to be prepared to evaluate new drugs and drug combinations for effectiveness and for toxicity. 
Precocious puberty and its management
Puberty is probably one of the most turbulent ages of man, heralding the onset of change from childhood into adult life and the acquisition of reproductive ability. The process starts at a variable age and lasts three to four years. The physical signs of puberty and the chronology of these events have been well documented by Tanner.' In girls the earliest sign is enlargement of the breast bud, occurring on average at the age of 11 with a range from 9 to 13 years. The first sign of puberty in boys is an increase in testicular size, which can be assessed volumetrically using an orchidometer.2 Since this event is not outwardly obvious, girls are widely believed to develop earlier than boys. In fact, testicular enlargement starts on average at the age of 11 1 (range 10 to 14). The pubertal growth spurt does, however, occur about two years earlier in girls than in boys. Menarche is a late event in puberty: the mean age is 13, but the range is from 11 to 15.
The timing of these events in normal puberty needs to be taken into account in defining precocious or early puberty. In general, development of the breast before 8 years or enlargement of the testes before 9 years, followed in each case by the progressive onset of other signs associated with normal puberty, is regarded as true central precocious puberty. The terminology used implies that the onset of puberty is due to premature activation of the hypothalamic-pituitarygonadal axis.3 In contrast, puberty is termed pseudoprecocious or false when the source of increased sex steroid secretion is independent of this axis, as in autonomous adrenal and gonadal tumours. 
